Mitochondrial DNA copy number and risk of cardiovascular disease and all-cause mortality: a systematic review and meta-analysis of observational studies

作者：Xueru Fu, Yang Zhao, Yamin Ke, Yajuan Gao, Mengmeng Wang, Yaobing Chen, Weifeng Huo, Longkang Wang, Wenkai Zhang, Yuying Wu, Xi Li, Dongdong Zhang, Fulan Hu, Dongsheng Hu, Ming Zhang · 发表于：QJM · 年份：2024 · DOI：10.1093/qjmed/hcae208 · 被引用次数：12 · 研究领域：Mitochondrial Function and Pathology、Metabolism and Genetic Disorders、Folate and B Vitamins Research

Increasing studies have explored the correlation of mitochondrial DNA copy number (mtDNA-CN) abnormalities with cardiovascular disease (CVD) and all-cause mortality; however, their findings are contradictory. This systematic review and meta-analysis sought to quantitatively summarize current studies to elucidate the impact of mtDNA-CN on CVD outcomes and all-cause mortality. Relevant studies were searched for in PubMed, Embase and Web of Science databases, up to 23 October 2023. Summary relative risks (RRs) and 95% confidence intervals (CIs) were calculated with the random-effects model. In total, 22 articles were included in the systematic review, 13 of which were included in the meta-analysis of CVD outcomes and 8 in all-cause mortality. Compared to the highest mtDNA-CN level, the summary RR (95% CI) for the lowest mtDNA-CN level was 2.09 (95% CI 1.59-2.75) for CVD, 1.70 (95% CI 1.29-2.24) for coronary heart disease (CHD), 1.43 (95% CI 1.15-1.79) for heart failure (HF), 1.88 (95% CI 1.08-3.28) for stroke and 1.33 (95% CI 1.21-1.47) for all-cause mortality. Lower mtDNA-CN may increase the risk of CVD, including CHD, HF and stroke, as well as all-cause mortality. MtDNA-CN is a potential predictor of CVD and all-cause mortality.